Related Experiment Video
Updated: May 29, 2026
Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
Statins inhibit iNOS-mediated microbicidal potential of activated monocyte-derived dendritic cells by an
Pilar M Domínguez1, María López-Bravo, Ulrich Kalinke
1Departamento de Inmunología y Oncología, Centro Nacional de Biotecnología, CSIC, Madrid, Spain.
Abstract:
Statins are prescribed to 25 million people worldwide for treating hypercholesterolemia and reducing the risk of cardiovascular diseases. However, the side effects of statins on immunity, and particularly on DC immunobiology, have not been analyzed in-depth. Here, we have investigated the impact of lovastatin treatment during monocyte differentiation into DCs on the responsiveness of the resulting monocyte-derived DCs (moDCs) to TLR-mediated activation. Lovastatin positively regulated TLR4 signaling in LPS-stimulated moDCs, leading to strong activation of p38 MAP-kinase paralleled by increased proinflammatory cytokine and IFN-β production. In contrast, lovastatin promoted negative regulation of IFN-β-mediated autocrine signaling through the IFN-αβ receptor, paralleled by low expression of the transcription factor IRF-1, leading to the inhibition of the enzymes iNOS and HO-1. Defective activation of iNOS/HO-1 resulted in limited cytoprotective capacity against ROS and reduced microbicidal potential. These data were validated using an in vivo model of Listeria monocytogenes infection, which revealed that iNOS activation by splenic inflammatory moDCs, specialized in NO and TNF-α production, was strongly reduced in lovastatin-treated, Listeria-infected mice. Statin treatment could have severe implications in immunity against pathogens due to defective iNOS/HO-1 metabolism activation in inflammatory moDCs that might lead to immune failure.
Insights
Statins like lovastatin impact immune cells called dendritic cells (DCs). Lovastatin impairs the microbicidal function of DCs, potentially leading to immune failure against pathogens.
Area of Science:
- Immunology
- Pharmacology
- Cell Biology
Background:
- Statins are widely used to treat high cholesterol and reduce cardiovascular disease risk.
- The impact of statins on immune cell function, particularly dendritic cells (DCs), remains incompletely understood.
Purpose of the Study:
- To investigate the effects of lovastatin on monocyte-derived dendritic cells (moDCs) and their immune response.
- To analyze lovastatin's influence on Toll-like receptor (TLR)-mediated activation and subsequent immune signaling pathways.
Main Methods:
- Monocytes were differentiated into moDCs in the presence of lovastatin.
- moDCs were stimulated with lipopolysaccharide (LPS) to activate TLR4 signaling.
- Analysis of signaling pathways (p38 MAP-kinase, IFN-β), cytokine production, and enzyme expression (iNOS, HO-1).
- In vivo validation using a mouse model of Listeria monocytogenes infection.
Main Results:
- Lovastatin enhanced TLR4 signaling and pro-inflammatory cytokine production in moDCs.
- Lovastatin inhibited IFN-β autocrine signaling, leading to reduced IRF-1 expression and decreased iNOS and HO-1 enzyme activity.
- Defective iNOS/HO-1 activation impaired the cytoprotective and microbicidal capacity of moDCs.
- In vivo, lovastatin treatment reduced iNOS activation in splenic inflammatory moDCs during Listeria infection.
Conclusions:
- Lovastatin treatment significantly alters DC immunobiology, impacting both pro-inflammatory responses and antimicrobial functions.
- The inhibition of iNOS/HO-1 metabolism in inflammatory moDCs by statins may compromise host defense against pathogens, potentially leading to immune failure.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:38Inflammation
01:30Inhibitors of Viral Protein Synthesis